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relapsed HIV-related non-Hodgkin's lymphoma who i.v. on days 5 and 7 (total dose 360 mg/m 2 ) and cytarabine underwent autologous bone marrow transplantation as a 250 mg/m 2 i.v. over 6 consecutive days (total dose 1500 rescue treatment. Their patient had significant baseline mg/m 2 ) and entered a further complete remission. Mainte-HIV-induced immunosuppression and developed several nance therapy consisted of cytarabine (20 mg/m 2 s.c. for opportunistic infections following the transplant. The 12 consecutive days, total dose 240 mg/m 2 every month) authors concluded that the immunological status of an HIV over 6 months. At that time, the question of an allogeneic carrier with a malignancy may dictate the way in which the intrafamilial bone marrow transplant was considered but malignancy is managed.
there was no compatible family donor. An unrelated alloIn support of this conclusion, we present the case of a geneic bone marrow was considered to be too risky and patient who was an asymptomatic HIV carrier and who was in any case not possible because HIV carriers could presented with acute myeloblastic leukemia in third relapse not be placed on transplant lists. and successfully underwent an autologous stem cell trans-A second relapse occurred in October 1994. The patient plantation as a rescue treatment.
was successfully treated with idarubicin 10 mg/m 2 on days 1, 3 and 5 (total dose 30 mg/m 2 ) and cytarabine 100 mg/m Correspondence: CM Farber, Unité de traitement des Immunodéficiences, 808, Rte de Lennik, 1070-Bruxelles, Belgium Figure 1 Evolution of CD4 + counts () and white blood cell counts (ć). Dates (month, year) on abscissa. Received 11 January 1997; accepted 2 June 1997 period of aplasia was complicated by the occurrence of an sidered good because the prognosis becomes worse after each relapse. invasive lung aspergillosis that was treated with amphoThis is the first autologous stem cell graft performed on tericin B. The duration of this third CR was likely to be an HIV carrier to our knowledge. The successive chemoshort and the probability of prolonged survival with contherapy treatments did not seem to activate the retroviral ventional chemotherapy only, was very poor.
3,4 High-dose infection in this patient and no opportunistic infections chemotherapy followed by autologous stem cell reinfusion occurred, although the CD4 + count decreased below 300 has been used to increase the percentage of long-term sur-CD4 + mm 3 (Figure 1 ). vivors in second CR. 4 A retrospective analysis from the This observation supports the conclusion of Gabarre et European Bone Marrow Transplantation (EBMT) registry al 1 that tolerance to autologous bone marrow or stem cell performed on 331 patients autografted in second CR transplant might correlate with a low viral burden. showed a leukemia-free survival of 33% at 8 years. 5, 6 Among recipients of autotransplants for AML between 1989 and 1995, reported courses of G-CSF (filgastrim) at the dosage of 10 g/kg
